Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Identify top index funds for a Roth IRA that offer tax-free growth, solid diversification, and low fees to support long-term retirement goals.
23,054 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
A new Brookings-FED working paper casts doubt on ai’s $2.2 trillion deficit savings, warning that disruption and poli...
XRP surged above key resistance as volume inflows and ETF demand point to renewed institutional interest. Regulators ...
NuScale Power has sparked excitement around small modular reactors, but does the hype translate into real investing u...
Bitcoin steadies near key levels as risk appetite returns amid mixed geopolitical headlines. This guide breaks down t...
As the market wrestles with SaaS cycles and AI disruption fears, monday.com stock has seen its share of monday blues....
As AMD prepares to report its second-quarter results, a bullish outlook centered on AI demand could dominate the conv...
London-listed Satsuma Technology is voting to sell its entire Bitcoin stash and delist, a decision that hinges on a J...
Apple is leaning into a capital-light AI model that runs on-device and with trusted partners. This story explains why...
In July’s session, AT&T surprised with subscriber growth that outweighed a revenue miss, lifting its stock and offeri...
Across Chicago and beyond, AI readiness in schools mirrors economic divides. This report examines funding gaps, acces...
Quanta PWR’s Q4 2025 results shed light on profitability, cash flow, and growth bets. This analysis breaks down the n...